

1 **The fiber knob protein of human adenovirus type 49 mediates**
2 **highly efficient and promiscuous infection of cancer cell lines**
3 **using a novel cell entry mechanism**

4 Alexander T. Baker^{1,2}, James A. Davies¹, Emily A. Bates¹, Elise Moses¹, Rosie M. Mundy¹, Gareth
5 Marlow¹, David K. Cole³, Carly M. Bliss^{1,3}, Pierre J. Rizkallah³, Alan L. Parker^{1*}

7 ¹Division of Cancer and Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN,
8 UK.

9 ²Current address: Department of Haematology and Oncology, Mayo Clinic, 13208 E Shea Blvd,
10 Scottsdale, Arizona, 85259, USA

11 ³Division of Infection and Immunity, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14
12 4XN, UK.

13 *Corresponding Author, ParkerAL@Cardiff.ac.uk

16 **Correspondence:**

17 Dr Alan Parker
18 Division of Cancer and Genetics
19 Cardiff University
20 Heath Park
21 Cardiff
22 CF14 4XN
23 Telephone: +44 2922 510 231
24 Email: ParkerAL@cardiff.ac.uk

26 **Word count**

27 Abstract: 249
28 Importance: 150
29 Main text: 4972
30 Figure legends: 929
31 Figure count: 5 Figures plus 2 tables

34 Running title: Ad49 fiber knob permits promiscuous cell entry

35 Abstract

36 The human adenovirus (HAdV) phylogenetic tree is diverse, divided across seven species and comprising
37 over 100 individual types. Species D HAdV are rarely isolated with low rates of pre-existing immunity,
38 making them appealing for therapeutic applications. Several species D vectors have been developed as
39 vaccines against infectious diseases where they induce robust immunity in pre-clinical models and early
40 phase clinical trials. However, many aspects of the basic virology of species D HAdV, including their basic
41 receptor usage and means of cell entry, remain understudied.

42 Here, we investigated HAdV-D49, which previously has been studied for vaccine and vascular gene
43 transfer applications. We generated a pseudotyped HAdV-C5 presenting the HAdV-D49 fiber knob
44 protein (HAdV-C5/D49K). This pseudotyped vector was efficient at infecting cells devoid of all known
45 HAdV receptors, indicating HAdV-D49 uses an unidentified cellular receptor. Conversely, a pseudotyped
46 vector presenting the fiber knob protein of the closely related HAdV-D30 (HAdV-C5/D30K), differing in
47 four amino acids to HAdV-D49, failed to demonstrate the same tropism. These four amino acid changes
48 resulted in a change in isoelectric point of the knob protein, with HAdV-D49K possessing a basic apical
49 region compared to a more acidic region in HAdV-D30K. Structurally and biologically we demonstrate
50 that HAdV-D49 knob protein is unable to engage CD46, whilst potential interaction with CAR is
51 extremely limited by extension of the DG loop. HAdV-C5/49K efficiently transduced cancer cell lines of
52 pancreatic, breast, lung, oesophageal and ovarian origin, indicating it may have potential for oncolytic
53 virotherapy applications, especially for difficult to transduce tumour types.

54 **Importance**

55 Adenoviruses are powerful tools experimentally and clinically. To maximise efficacy, the development of
56 serotypes with low pre-existing levels of immunity in the population is desirable. Consequently,
57 attention has focussed on those derived from species D, which have proven robust vaccine platforms.
58 This widespread usage is despite limited knowledge in their basic biology and cellular tropism.

59 We investigated the tropism of HAdV-D49, demonstrating it uses a novel cell entry mechanism that
60 bypasses all known HAdV receptors. We demonstrate, biologically, that a pseudotyped HAdV-C5/D49K
61 vector efficiently transduces a wide range of cell lines, including those presenting no known adenovirus
62 receptor. Structural investigation suggests that this broad tropism is the result of a highly basic
63 electrostatic surface potential, since a homologous pseudotyped vector with a more acidic surface
64 potential, HAdV-C5/D30K, does not display a similar pan-tropism. Therefore, HAdV-C5/D49K may form a
65 powerful vector for therapeutic applications capable of infecting difficult to transduce cells.

66 Introduction:

67 Human adenoviruses are divided into seven species, A-G(1). These non-enveloped, icosahedral viruses
68 have garnered significant interest as therapeutic vectors since they can be grown and purified to high
69 titers, and because the double-stranded DNA genome is readily amenable to genetic modification,
70 enabling the overexpression of therapeutic transgenes(2, 3). Similar techniques can also be applied to
71 genetically alter the virus structural genes, creating modified viral tropisms which are retained by
72 progeny virions after replication.

73 Clinically, adenoviruses have been developed as vectors for gene therapy, vaccines, and as oncolytic
74 virotherapies(1, 4, 5). However, efficacy in these applications can be hampered by pre-existing immunity
75 against the therapeutic vector in the population resulting from prior exposure to the wild type
76 pathogen. Such pre-existing immunity is likely to reduce the therapeutic index of such systems, due to
77 rapid and efficient removal of the engineered therapeutic agent by the reticuloendothelial system(6, 7).
78 This is especially relevant where the therapeutic is based on the most commonly studied species C
79 adenovirus, human adenovirus type 5 (HAdV-C5), where neutralising antibodies are found in ~90% of
80 patients from sub-Saharan Africa and ~30% of a Scottish patient cohort(8, 9).

81 A promising means to circumvent pre-existing immunity is through the development of viruses with
82 naturally low seroprevalence rates as therapeutic agents. For example, vaccines have been developed
83 using chimpanzee adenoviruses which have little to no seroprevalence in humans. However, it appears a
84 significant percentage of some populations may still harbour some immunity to chimpanzee
85 adenoviruses, as observed in a cohort from China(10).

86 Most attempts to develop adenoviruses with low seroprevalence have focused on those derived from
87 species B or D, due to their comparative rarity(5, 9, 11). The most clinically advanced of these are HAdV-
88 D26 and Enadenotucirev (formerly ColoAd1)(12). Enadenotucirev was developed by evolution of a panel

89 of different adenovirus strains to select for recombinants with rapid replication in tumour cells. The
90 resultant recombinant was predominantly HAdV-B11 with some elements of HAdV-B3, and has
91 progressed into clinical trials as a novel cancer therapeutic(13, 14). HAdV-D26, is a replication deficient
92 vector and the basis of the Ad26.ZEBOV vaccine against Ebola virus, currently under evaluation in the
93 PREVAIL and PREVAC studies(15, 16).

94 Many species D adenoviruses have previously been evaluated for their potential as vaccines, gene
95 therapies, and oncolytic viruses(1, 5, 9, 11). One with particularly low seroprevalence rates is HAdV-D49.
96 In a cohort of 100 Belgian individuals only 2% had HAdV-D49 positive sera, whilst no pre-existing
97 immunity against HAdV-D49 was detected in 103 Scottish patients(8, 17). Prevalence is somewhat
98 higher in sub-saharan Africa with 22% of 200 patients presenting neutralising antibodies (nAbs),
99 highlighting significant geographical variation in seroprevalence(9).

100 HAdV-D49 was first isolated from the faeces of a human with no observed disease, and later from Dutch
101 patients(18, 19). It was then isolated from nosocomial epidemic keratoconjunctivitis infections(20, 21),
102 but is most associated with patients who are immunocompromised due to HIV infection(22). A study of
103 adenovirus infections in patients from the UK and Netherlands found 11 instances of HAdV-D49
104 infection in 183 HIV positive patients (6% HAdV-D49 positive), compared to just two instances in 2301
105 tested healthy patients (0.09% HAdV-D49 positive)(19).

106 Previous studies suggest that HAdV-D49 may be effective as a vaccine vector. A vaccine vector based on
107 HAdV-D49 has been evaluated previously for its ability to protect against simian immunodeficiency virus
108 (SIV) challenge. This vector induced strong anti-SIVGag CD8⁺ mediated immunity to SIV, greater than the
109 comparable HAdV-C5 based vector(23). Another study sought to exploit HAdV-D49 a gene therapy to
110 reduce excessive smooth muscle cell proliferation in vascular conduits following bypass grafting. This
111 study demonstrated that HAdV-D49 was efficient at infecting endothelial cells and vascular smooth

112 muscle cells, even after short exposure times(8). Studies in CAR, CD46, and α 2-3 linked sialic acid
113 expressing cells have previously suggested that HAdV-D49 may engage CD46 as a cellular receptor,
114 although the effects observed were small(23).

115 Despite these studies and the development of HAdV-D49 as a therapeutic agent, there remains little
116 information surrounding the basic biology of HAdV-D49 and its means of cellular engagement. Here, we
117 investigate the tropism of HAdV-D49, focussing on the fiber knob protein as the major mediator of
118 cellular attachment, and evaluate the potential utility of a pseudotyped HAdV-C5/D49K vector to infect
119 a range of cancer cell lines.

120 Results and Discussion

121 HAdV-C5/D49K is not dependent on any known adenovirus receptor for cell entry

122 To investigate the receptor usage of human adenovirus type 49 fiber knob protein we generated a
123 replication incompetent HAdV-C5 vector pseudotyped with the fiber knob protein of HAdV-D49 (HAdV-
124 C5/D49K), expressing either green fluorescent protein (GFP) or luciferase as transgenes. We also
125 produced a replication deficient HAdV-C5 based pseudotyped vector with the whole fiber protein,
126 including both the fiber shaft and fiber knob of HAdV-D49, expressing luciferase (HAdV-C5/D49F). This
127 pseudotyping approach is a well-established means to investigate the fiber knob in the context of a well
128 understood, replication incompetent virus(1, 24). Using these pseudotyped vectors, we performed
129 transduction assays in CHO cells expressing common adenovirus receptors (Figure 1). CHO-K1 cells do
130 not express any known adenovirus receptor, whilst CHO-CAR cells express the HAdV-C5 receptor,
131 coxsackie and adenovirus receptor (CAR), and CHO-BC1 cells express the BC1 isoform of CD46, the major
132 receptor for species B1 adenovirus, which includes HAdV-B35.

133 The ability of HAdV-C5/D49K to transduce cell lines was compared to similar GFP expressing replication
134 incompetent vectors HAdV-C5 and HAdV-C5/B35K, which engage CAR and CD46 as receptors,
135 respectively(24–26). HAdV-C5/D35K was unable to transduce CHO-CAR, due to the lack of CD46, whilst
136 HAdV-C5 transduced CHO-CAR cells efficiently due to the high levels of CAR expressed. HAdV-C5/D49K
137 transduced CHO-CAR cells efficiently, but slightly less so (by ~20%) compared to HAdV-C5 (Figure 1A). In
138 CHO-BC1 cells, transduction by HAdV-C5 was inefficient, due to the absence of CAR, whilst HAdV-C5/B35
139 transduced these cells with almost 100% efficiency, due to the presence of high affinity HAdV-B35
140 receptor, CD46. HAdV-C5/D49K demonstrated a similar ability to HAdV-C5-B35K to transduce CHO-BC1
141 cells (Figure 1B). In CHO-K1 cells neither HAdV-C5 nor HAdV-C5/B35K were able to efficiently transduce
142 the cells due to the absence of known adenovirus cell surface receptors. HAdV-C5/D49K, however, was

143 able to transduce these cells efficiently, indicating that HAdV-D49K is able to infect cells efficiently and
144 independently of CAR or CD46 (Figure 1C), thus indicating HAdVC5/D49K engages an alternative cellular
145 receptor. Interestingly, we also observed, in this and later experiments, that HAdV-C5/D49K was less
146 efficient at infecting CHO-CAR cells (Figure 1A) compared to non-CAR expressing CHO cell types (Figure
147 1B-C). These data indicate that the presence of CAR may actively reduce the efficiency of transduction of
148 HAdVC5/D49K compared to levels of transduction in the absence of CAR in the same cell line
149 background.

150 At 385 amino acids in length, the native HAdV-D49 protein is significantly shorter than the equivalent
151 HAdV-C5 fiber protein, which is 581 amino acids in length. This manifests as a naturally shorter and less
152 flexible fiber shaft in HAdV-D49 compared to that of HAdV-C5. This shortened fiber shaft length may
153 impact upon viral infectivity, resulting in trapping of adenoviral particles within late endosomes due to
154 the decreased endosomolytic activity of shorter shafted adenoviral particles(27), reviewed
155 elsewhere(28). To assess the impact of pseudotyping the entire short fiber protein from HAdV-D49 on
156 viral infectivity, we performed similar transduction assays using CHO-K1 cells. Consistent with engaging
157 an alternative receptor on CHO-K1 cells, the HAdV-C5/D49F whole-fiber pseudotyped vector efficiently
158 transduced CHO-K1 cells, where HAdV-C5 was unable. Also consistent with previous observations of
159 shorter shafted HAdVs potentially displaying reduced infectivity due to altered or less efficient
160 intracellular trafficking post-entry, the HAdV-C5/D49F was less efficient than the “knob-only”
161 pseudotype HAdV-C5/D49K at infecting CHO-K1 cells (Figure 1D).

162 We performed similar transduction assays using CHO-K1 and SKOV-3 ovarian cancer cells with and
163 without pre-treatment with either heparinase or neuraminidase to determine the ability of
164 HAdVC5/D49K to bind heparan sulphate proteoglycans (HSPGs) or sialic acid, respectively, to mediate
165 cellular infection (Figure 2). As a positive control for heparinase activity we compared HAdV-C5/D49K
166 infectivity to that of HAdV-C5 in the presence and absence of coagulation factor X (FX), a blood

167 coagulation factor which can facilitate infection of some adenovirus by binding to the viral hexon and
168 cellular heparan sulfate proteoglycans (HSPGs)(29). We observed in CHO-K1 and SKOV-3 cells that
169 transduction levels of HAdV-C5 alone were poor (Figure 2A, B), but were significantly enhanced by the
170 presence of FX, enabling cell entry through cellular HSPGs (30–32). Treatment with heparinase to cleave
171 HSPGs reduced transduction efficiency to that of HAdV-C5 alone. HAdV-C5/D49K transduction efficiency
172 was unaffected by treatment with heparinase (Figure 2A, B), indicating that HAdV-D49 is unlikely to
173 utilise HSPGs for cell entry.

174 Treatment with neuraminidase to remove cellular sialic acid did not alter the ability of any of the viruses
175 to transduce CHO-K1 cells (Figure 2C), as we previously demonstrated to show the involvement of sialic
176 acid in HAdV-C5/D26K infection(24). In SKOV-3 cells, removal of sialic acid actually enhanced the
177 transduction mediated by HAdV-C5/D49K and HAdV-C5/B35K, an effect which we have previously
178 observed by neuraminidase treatment in SKOV-3 cells (Figure 2D)(24, 33, 34). This effect could be a
179 result of the removal of sialic acid enhancing non-specific charge-based interactions between the cell
180 surface and viral capsid. Regardless, these data do not support a role for sialic acid in HAdV-C5/D49K cell
181 infection.

182 The transduction affinity of HAdV-C5/D49K in the experiments in Figure 2 was noticeably weaker than in
183 the CHO cell experiments (Figure 1). This is due to the methodology used in each experiment. In the
184 transduction experiments (Figure 1), cells were incubated with virus at 37°C for three hours. For studies
185 evaluating the role of sialic acid and HSPGs, cells were pre-treated with enzyme for one hour at 37°C.
186 Then virus was then incubated with cells on ice for one hour following enzymatic digestion to prevent
187 repair and reconstitution of the cleaved heparin/sialic acid. This incubation on ice (and for a shorter
188 period of time) likely decreases viral internalisation during the absorption step, seemingly more
189 profoundly for HAdV-C5/D49K than for the HAdV-C5 suggesting weaker binding at the cell surface or a
190 comparatively low frequency of cell surface receptor.

191 Desmoglein 2 (DSG2) is the other remaining well-established adenovirus receptor. DSG-2 is described to
192 interact with species BII adenovirus, including HAdV-B3K, via low affinity, avidity dependent
193 mechanism(35). We investigated whether HAdV-D49K might also interact with DSG2 by utilising surface
194 plasmon resonance (SPR), which we have previously used to establish a 66.9 μ M affinity between DSG2
195 and HAdV-D3K(36). HAdV-D49K had no detectable affinity for DSG2 (Figure 3A), an unsurprising finding
196 as DSG2 has never been observed as a receptor for any adenovirus outside of species B.

197 **HAdV-D49 fiber knob can interact with CAR, but does not require it for cell entry**

198 We also used SPR to further probe the binding affinity of HAdV-D49K, and a mutant version, HAdV-
199 D49.KO1.K, for CD46 and CAR. This HAdV-D49.KO1.K mutant, harbours the KO1 mutations S408E and
200 P409A in the fiber knob AB loop, previously shown to ablate CAR binding in HAdV-C5K(37). The structure
201 of the HAdV-D49.KO1.K fiber knob is also presented (Table 1, PDB 6QPO)(38). As predicted, we did not
202 observe binding between either fiber knob protein and CD46. However, we did observe HAdV-D49K
203 binding to CAR with a detectable 0.19 μ M affinity which was ablated by the KO1 mutation (Figure 3A).

204 We performed IC₅₀ binding studies using recombinant HAdV-D49K protein on CHO-CAR and CHO-BC1
205 cells and assessed the ability of the recombinant fiber knob protein to inhibit the binding of anti-CAR or
206 CD46 antibodies, respectively (Figure 3B). HAdV-D49K was able to block anti-CAR antibody binding to
207 CHO-CAR cells in a dose dependent manner (IC₅₀ = 0.16 μ g/10⁵ cells, Figure 3B). However, no IC₅₀ could
208 be derived by using HAdV-D49K to block CD46 on CHO-BC1 cells, where HAdV-D49K was unable to
209 achieve more than 20% inhibition of antibody binding, suggesting weak or incidental CD46 interactions
210 (Figure 3B). Therefore, these data support the findings from SPR and transduction experiments that
211 HAdV-D49K may bind CAR with low affinity, but does not bind CD46.

212 Our earlier findings indicated that HAdV-C5/D49K is not dependent upon CAR for cell entry (Figure 1),
213 however our *in vitro* biological inhibition and SPR assays demonstrate CAR binding affinity (Figure 3A, B).

214 We further investigated this finding by performing transduction blocking experiments using the CAR
215 engaging HAdV-C5 and HAdV-C5/D49K with recombinant fiber knob protein of each virus in CHO-CAR
216 and CHO-K1 cells. As predicted, pre-incubation of CHO-CAR cells with recombinant HAdV-C5K efficiently
217 inhibited HAdV-C5 infection (Figure 3C), whilst blocking with HAdV-D49K inhibited infection by HAdV-C5
218 by approximately 50% (Figure 3D). Infecting CHO-CAR cells with HAdV-C5/D49K pseudotype and
219 attempting to block using HAdV-C5K (Figure 3E) or HAdV-D49K (Figure 3F) did not significantly inhibit
220 transduction efficiency. Finally, infection of CHO-K1 cells by HAdV-C5/D49K and blocking with HAdV-C5K
221 did not significantly inhibit transduction efficiency (Figure 3G), whilst blocking with HAdV-D49K reduced
222 transduction efficiency by approximately 50% (Figure 3H).

223 These data confirm that HAdV-D49K is capable of binding to CAR, albeit at approximately 1000x lower
224 affinity than HAdV-C5(36), but in a manner able to inhibit HAdV-C5 binding. These data confirm HAdV-
225 C5/D49K is capable of entering cells through a non-CAR mediated pathway, since HAdV-C5K cannot
226 inhibit HAdV-C5/D49K transduction in CHO-CAR cells (Figure 3E). Interestingly, HAdV-C5/D49K was able
227 to inhibit its own viral infection only in the absence of CAR (Figure 3H).

228 One potential explanation for this activity is that the unknown alternative receptor to CAR has a lower
229 affinity for HAdV-D49K than CAR. Therefore, in the presence of CAR the recombinant fiber knob would
230 be sequestered on the higher affinity CAR receptor leaving the alternative receptor free to interact with
231 the virus. A low affinity receptor would also, likely, depend upon avidity, so might not be observed with
232 single trimers of HAdV-D49K; a similar effect has previously been observed with HAdV-B3K and
233 DSG2(39) and CD46(40). This is supported by the observation that HAdV-D49K cannot transduce cells as
234 efficiently when incubated on ice in the absence of CAR, while HAdV-C5 and HAdV-C5/B35K, which form
235 high affinity receptor interactions, are unencumbered (Figure 2).

236 **HAdV-D49K may bind cells through a charge dependent mechanism**

237 To investigate other closely related HAdV with homologous fiber-knob proteins we performed a BLASTp
238 search using the HAdV-D49K amino acid sequence. This search revealed that the HAdV-D30K protein is
239 highly homologous to HAdV-D49K, differing in just 4 amino acid residues (Figure 4A).

240 We solved the crystal structures of HAdV-D30K (Figure 4B) and HAdV-D49K (Figure 4C). Diffraction data
241 collection statistics for these structures are provided in Table 1. We demonstrate that structurally,
242 HAdV-D30K and HAdV-D49K are highly homologous (RMSD = 0.292\AA^2). Residue 338 is not surface
243 exposed on either fiber knob protein and is likely to be functionally homologous (HAdV-D49 =
244 Isoleucine338, HAdV-D30 = Valine338). However, the remaining 3 residue differences, E238K, G330A,
245 and Q331K (HAdV-D30K → D49K) are surface exposed at the apex of each fiber knob monomer (Figure
246 4D, E). The E238K and Q331K substitutions have opposing charges.

247 We investigated the transduction efficiency of HAdV-C5/D30K compared to HAdV-C5/D49K, HAdV-C5,
248 HAdV-C5.KO1, and HAdV-C5/D49.KO1.K in CHO-CAR (Figure 4F) and CHO-K1 cells (Figure 4G). HAdV-C5
249 infected CHO-CAR cells efficiently whilst the CAR-binding ablated KO1 mutant version did not, whilst
250 HAdV-C5/49K and the corresponding mutant HAdV-C5/49KO1.K infected CHO-CAR cells with similar
251 efficiency as observed for HAdV-C5/D49K in Figure 1A. HAdV-C5/D30K infected CHO-CAR cells with
252 approximately 40% efficiency (Figure 4F). In CHO-K1 cells HAdV-C5/D49K and the KO1 mutant were the
253 only viruses which achieved efficient transduction. Surprisingly, given the high homology to HAdV-
254 C5/D49K, the HAdV-C5/D30K pseudotype was inefficient in transducing CHO-K1 cells (<5% GFP⁺, Figure
255 4G).

256 This profound difference in transduction efficiency between HAdV-C5/D30K and HAdV-C5/D49K must be
257 dependent upon the 3 surface exposed amino acid differences. We investigated the effect of the
258 opposing charges at residue substitutions 238 and 331 (Figure 4A-E) by modelling the electrostatic

259 surface potential of the two fiber knob proteins, based on our crystal structures (Figure 5). The surface
260 potential maps reveal that whilst structural homology was high, they present radically different
261 electrostatic surface potential distributions. HAdV-D30K is significantly more acidic (pI = 5.57) than
262 HAdV-D49K (pI = 8.26) (Figure 5).

263 Thus, it seems probable that the interaction with the unknown cell surface receptor requires basic
264 electrostatic potential. This is commensurate with the previous inference that its receptor is likely to be
265 low affinity, as electrostatic interfaces are often observed to be less stable than their ionic counterparts.
266 It is possible that the electrostatic potential differences explain the reduced transduction affinity
267 observed in HAdV-C5/D30K compared to HAdV-C5/D49K in CHO-CAR cells. Should the strong charge on
268 HAdV-D49K be opposed to that on the surface of CAR, this could enhance the interaction stability and
269 therefore overall virus affinity. It seems unlikely that the residue substitutions themselves would
270 strongly influence CAR affinity as they occur at the apex of the fiber knob, an area which is not critical
271 to the CAR interface(1).

272 **HAdV-C5/D49K is able to efficiently infect a large range of cancer cell lines**

273 Given HAdV-C5/D49K infects cells independently of known adenovirus receptors we hypothesised that it
274 may form the basis of an efficient vector for cancer virotherapy applications. We therefore compared its
275 transduction efficiency to that of HAdV-C5 in panels of pancreatic, breast, oesophageal, colorectal,
276 ovarian and lung cancer cell lines (Table 2).

277 In pancreatic cancer cell lines HAdV-C5/D49K was consistently more efficient at cellular transduction
278 than HAdV-C5. This improved activity ranged between 4.2x more efficient in MiaPaCa2 cells to 210.9x
279 more efficient in BxPc3 cells. The most effectively transduced cell line was Panc10 cells, producing
280 7.2×10^6 RLU/mg of fluorescence, compared to the least efficient at just 4.0×10^5 RLU/mg in Panc0403
281 cells. This suggests that the large differences between HAdV-C5/D49K and HAdV-C5 transduction levels

282 are likely due to the variability in the expression of CAR. A similarly broad range of different relative
283 infection efficiencies were observed in the breast cancer cell lines studied. In MCF7 cells and BT20 cells
284 HAdV-C5/D49K was nearly 500-fold more efficient at transducing the cells due to these cells expressing
285 low levels of CAR, with consequent poor levels of HAdV-C5 mediated transduction (Table 2).

286 DLD-1 colorectal cancer cells were efficiently transduced by both HAdV-C5 and HAdV-C5/D49K vectors,
287 at 5.0×10^6 and 6.0×10^6 RLU/mg respectively. This is the only cell line where no significant difference in
288 infectivity was observed. A427 lung carcinoma cells are the only line where HAdV-C5 mediated cellular
289 transduction was more efficient than HAdV-C5/D49K (0.6x). Whilst HAdV-C5/D49K transduced A427 cell
290 very efficiently (7.2×10^6 RLU/mg) HAdV-C5 achieved unusually high transduction efficiency (1.2×10^7
291 RLU/mg) (Table 2). Therefore, this result is not due to inefficient HAdV-C5/D49K transduction, but
292 unusually efficient HAdV-C5 transduction.

293 Conclusions

294 Previous experiments using whole HAdV-D49 virus concluded that it utilises CD46 as its primary cellular
295 receptor(23). The data described, generated using either purified HAdV-D49 fiber knob protein or a
296 pseudotyped HAdV-C5/D49K vector, clearly demonstrate CD46 to be implausible as a receptor for HAdV-
297 D49.

298 We demonstrate that the HAdV-D49 fiber knob has a weak affinity for CAR, although it is not dependent
299 upon this interaction to mediate efficient cell entry, and in fact the presence of CAR may inhibit cellular
300 transduction. In support of this we show a mutant vector, HAdV-C5/D49.KO1.K, containing mutations
301 within the fiber knob domain which ablate CAR affinity, retained the ability to efficiently transduce cells
302 in the absence of any detectable binding to CAR. Based on the low efficiency by which HAdV-C5/D49K
303 transduced cells when absorbed on ice and the observation that HAdV-D49K is only capable of inhibiting

304 HAdV-C5/D49K transduction in the absence of CAR, we tentatively suggest that the unknown receptor is
305 likely to be bound with weak affinity and virus attachment may be avidity dependent.

306 Regardless of the mechanism of interaction this study strongly suggests there is an as yet unknown
307 adenovirus receptor or mechanism of cell entry which mediates efficient transduction of a broad range
308 of cell lines. This is demonstrated by its ability to efficiently infect every cell line tested, throughout this
309 study. The weakest observed transduction was in Panc0403 cells where it achieved 4.0×10^5 RLU/mg of
310 luminescence. Whilst this is not a particularly strong transduction efficiency, it is still significantly higher
311 (33.0x, $P < 0.05$) than that of HAdV-C5. It is likely, therefore, that the HAdV-C5/D49K vector described
312 here may be useful in biotechnology applications to efficiently express proteins in difficult to transduce
313 cell lines.

314 HAdV-C5/D49K represents a highly efficient gene transfer vehicle which is not restricted by any known
315 adenovirus tropism. It possesses a broad range of infectivity and has potential as both a laboratory
316 reagent, for the transient expression of transgenes, and as a therapeutic vaccine or oncolytic virus. For
317 oncolytic applications, it is likely that further refinement, such as the introduction of mutations known
318 to confer tumour selective replication, such as dl24 mutation(41–43) or the use of tumour specific
319 promoters such as hTERT(44) or survivin(45) to drive transgene therapeutic expression selectively within
320 tumour cells will be necessary to ensure tight tumour selectivity.

321 **Materials and Methods**

322 **GFP transduction assay**

323 Adherent cells were seeded into a Nunc delta surface 96-well cell culture plate (ThermoFisher) at a
324 density of 5×10^4 cells/well in 200 μ l of cell culture media and left to adhere overnight at 37°C in a 5% CO₂
325 humidified atmosphere. Media was removed and cells washed twice with 200 μ l of PBS. Virus was added
326 at the desired concentration in 200 μ l of serum free RPMI 1640 and incubated for 3hrs. The virus
327 containing media was then removed and replaced with complete cell culture media and the cells
328 incubated for a further 45hrs. Cell culture media was then removed, the cells washed twice with 200 μ l
329 of PBS, trypsinised in 50 μ l of 0.05% Trypsin-EDTA (Gibco), and dissociated by pipetting. The trypsinised
330 cells were transferred to a 96-well V-bottom plate (ThermoFisher), neutralised with 100 μ l of complete
331 cell culture media, and pelleted by centrifugation at 1200RPM for 3mins. Supernatant was removed, the
332 cells washed once in 200 μ l of PBS, and resuspended in 100 μ l of 2% PFA (PBS containing 2% w/v
333 paraformaldehyde) and incubated at 4°C for 15mins. Cells were again pelleted, washed twice in 200 μ l
334 PBS, then resuspended in 200 μ l PBS prior to analysis by flowcytometry.

335 Samples were analysed by flow cytometry on Attune NxT (ThermoFisher), voltages were set prior to
336 each experiment, for each cell type, using an uninfected cell population treated identically. Data was
337 analysed using FlowJo v10 (FlowJo, LLC), gating sequentially on singlets, cell population, and GFP
338 positive cells. Levels of infection were defined as the percentage of GFP positive cells (% +ve), and/or
339 Total Fluorescence (TF), defined as the percentage of GFP positive cells multiplied by the median
340 fluorescent intensity (MFI) of the GFP positive population. These measures are distinct in that % +ve
341 describes the total proportion of cells infected, and TF describes the total efficiency of transgene
342 delivery.

343 **Luciferase transduction assay**

344 Luciferase infectivity assays were performed using the luciferase assay system kit (Promega). Cells were
345 seeded into a Nunc delta surface 96-well cell culture plate (ThermoFisher) at a density of 2×10^4
346 cells/well in 200 μ l of cell culture media and left to adhere overnight at 37°C in a 5% CO₂ humidified
347 atmosphere. Media was removed and cells washed once with 200 μ l of PBS. Luciferase transgene
348 encoding replication incompetent viruses were added to the wells at the required titre in 200 μ l of serum
349 free RPMI 1640 and incubated for 3hrs. The virus containing media was then removed and replaced with
350 complete cell culture media and the cells incubated for a further 45hrs. Cell culture media was then
351 removed, the cells washed twice with 200 μ l of PBS, and were then lysed in 100 μ l of cell culture lysis
352 buffer (part of the Promega kit) diluted to 1x in ddH₂O. The plate was then frozen at -80°C.

353 After thaw, 10 μ l of lysate from the cell culture plate mixed then was transferred to a white Nunc 96-
354 microwell plate (ThermoFisher) and 100 μ l of luciferase assay reagent (Promega Kit) added. Luciferase
355 activity was then measured in relative light units (RLU) by plate reader (Clariostar, BMG Labtech). Total
356 protein concentration was determined in the lysate using the Pierce BCA protein assay kit
357 (ThermoFisher) according to the manufacturers protocol, absorbance was measured on an iMark
358 microplate absorbance reader (BioRad).

359 Relative virus infection was determined by normalising the measured luciferase intensity to the total
360 protein concentration (RLU was divided by protein concentration). This gave a final infectivity readout in
361 RLU/mg of protein.

362 **Blocking of virus infection with recombinant fiber knob protein**

363 This assay was also performed using the luciferase assay system kit (Promega). Cells were seeded into a
364 Nunc delta surface 96-well cell culture plate (ThermoFisher) at a density of 2×10^4 cells/well in 200 μ l of
365 cell culture media and left to adhere overnight at 37°C in a 5% CO₂ humidified atmosphere. Media was

366 removed and cells washed 2x with 200µl of cold PBS and the plate cooled on ice. 20pg/cell of
367 recombinant adenovirus fiber knob was added to each well in 200µl of cold PBS and incubated on ice in
368 a 4°C cold room for 1hr. Media was then removed and luciferase transgene encoding replication
369 incompetent viruses added to the necessary wells at the required titre in 200µl of cold serum free RMPI
370 1640 and incubated on ice in a 4°C cold room for 1hr. The virus containing media was then removed and
371 replaced with complete cell culture media and the cells incubated for a further 45hrs under normal cell
372 culture conditions. From this point forward the assay is identical to the GFP and luciferase transduction
373 assays.

374 **Heparinase and Neuraminidase transduction assays**

375 Cells were seeded at a density of 5×10^4 cells/well in a flat bottomed 96 well cell culture plate and
376 incubated overnight at 37°C to adhere. Cells were washed twice with 200µl of PBS. 50µl of
377 neuraminidase (from Vibrio Cholera, Merk) at a concentration of 50mU/ml, or 50µl of Heparinase III
378 (from Flavobacterium heparinum, Merck) at a concentration of 1U/ml was diluted in serum free media,
379 added to the appropriate wells, and incubated for 1hr at 37°C. Cells were cooled on ice and washed
380 twice with 200µl of PBS. Green Fluorescent Protein (GFP) expressing, replication incompetent viruses
381 were added to the appropriate wells at a concentration of 5000 viral particles per cell, in 100µl of serum
382 free media, at 4°C, and incubated on ice for 1hr. Serum free media alone was added to uninfected
383 control wells. Cells were washed twice with 200µl of cold PBS, complete media added (DMEM, 10% FCS)
384 and incubated for a further 48hrs at 37°C. Cells were then trypsinised and transferred to a 96 well V-
385 bottom plate, washed twice in 200µl of PBS and fixed in 2% paraformaldehyde containing PBS for
386 20mins before wash, and resuspension in 200µl of PBS.

387 Samples were analysed by flow cytometry on Attune NxT (ThermoFisher), voltages were set prior to
388 each experiment, for each cell type, using an uninfected cell population treated identically. Data was

389 analysed using FlowJo v10 (FlowJo, LLC), gating sequentially on singlets, cell population, and GFP
390 positive cells. Levels of transduction were defined as the percentage of GFP positive cells (% +ve), and/or
391 Total Fluorescence (TF), defined as the percentage of GFP positive cells multiplied by the median
392 fluorescent intensity (MFI) of the GFP positive population. These measures are distinct in that % +ve
393 describes the total proportion of cells infected, and TF describes the total efficiency of transgene
394 delivery.

395 **Surface Plasmon Resonance**

396 Surface plasmon resonance was performed, in triplicate, as previously described, using recombinant
397 HAdV-D49K protein(36). Approximately 5000 RU of Recombinant Human Desmoglein-2 Fc Chimera
398 Protein (R&D Systems, Catalogue number 947-DM-100) was amine coupled to a CM5 sensor chip at a
399 slow flow-rate of 10 μ l/min to ensure uniform distribution on the chip surface.

400 **Competition Inhibition Assay**

401 Competition inhibition assays of antibody binding to cell surface receptors were performed as previously
402 described(36).

403 **Generation of recombinant fiber knob proteins**

404 Recombinant fiber knob proteins used in transduction inhibition, antibody blocking, and crystallisation
405 experiments were produced as previous described(24, 36). Briefly, pQE-30 vectors containing the
406 sequence of the relevant fiber knob protein, spanning from 13 amino acids preceding the TLW motif to
407 the stop codon, were transformed into SG13009 E.coli harbouring the pREP-4 plasmid. 1L of these E.coli
408 were grown to OD0.6 and protein expression induced with a final concentration of 0.5mM IPTG. E.coli
409 were harvested by centrifugation and resuspended in 50ml lysis buffer (50 mM Tris, pH 8.0, 300 mM
410 NaCl, 1% (v/v) NP40, 1 mg/ml Lysozyme, 1 mM β -mercaptoethanol). Sample was then loaded onto a

411 HisTrap FF Crude column and eluted by imidazole. Fractions determined to contain protein of interest
412 were then concentrated to <1ml total volume and purified by size exclusion chromatography using a
413 Superdex 200 10/300 GL Increase column.

414 **Fiber knob protein crystallisation and structure determination by X-Ray** 415 **crystallography**

416 HAdV-D49K, HAdV-D49.KO1.K, and HAdV-D30K were crystallised in the same manner as previously
417 described(24, 36). Both HAdV-D49K and HAdV-D49.KO1.K crystals formed in 0.1M MMT, 25% w/v
418 PEG1500, whilst HAdV-D30K crystallised in 0.1M SPG, 25% w/v PEG 1500. All crystals formed in 2-7 days
419 in sitting drop format. Data collection statistics are described in Table 1 and the structures were solved
420 by molecular replacement using PDB 6FJN.

421 **Calculation of electrostatic surface potentials and pIs**

422 Electrostatic surface potential and isoelectric points were calculated at pH 7.2 using the PDB2PQR Server
423 (V 2.1.1)(46) as previous described(24).

424 **RMSD calculation, sequence alignment, and imaging of crystal structures**

425 Alignments were performed using the Clustal Omega multiple sequence alignment algorithm and
426 visualised with BioEdit(47, 48). RMSD calculations were performed using the 'align' command in PyMOL
427 2.0, which was also used to visualise protein structures(49).

428 **Acknowledgements**

429 ATB was funded by a Tenovus Cancer Care PhD studentship (reference PhD2015/L13) to ALP. JAD is
430 funded by a Cancer Research UK Biotherapeutic Programme award (reference C52915/A29104) to ALP.
431 EAB is supported by a Cardiff University School of medicine PhD studentship to ALP. EM is supported by

432 a Wellcome Trust ISSF Translational Kickstarter Award (reference 517732) to ALP. RMM was supported
433 by the Cardiff University Research Opportunities Placement (CUROP) to ALP. GM was supported by a
434 Cancer Research UK ECMC centre award (C7838/A25173). CMB is supported by a Wellcome Trust ISSF
435 Fellowship (reference AC1170IF04). PJR and ALP are funded by HEFCW. The authors acknowledge the
436 Diamond Light Source for beamtime (proposal MX18812) and the staff of beamline I03 for assistance
437 with diffraction data collection. The authors acknowledge Johanne Pentier for technical assistance with
438 SPR data collection, as well as Aaron Wall and Anna Fuller for assistance with FPLC.

References

1. Baker AT, Aguirre-Hernández C, Halldén G, Parker AL. 2018. Designer Oncolytic Adenovirus: Coming of Age. *Cancers* 10:201.
2. Russell WC. 2009. Adenoviruses: update on structure and function. *J Gen Virol* 90:1–20.
3. Stanton RJ, McSharry BP, Armstrong M, Tomasec P, Wilkinson GWG. 2008. Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function. *BioTechniques* 45:659–662, 664–668.
4. Alba R, Baker AndrewH, Nicklin StuartA. 2012. Vector Systems for Prenatal Gene Therapy: Principles of Adenovirus Design and Production, p. 55–84. *In* Coutelle, C, Waddington, SN (eds.), Prenatal Gene Therapy. Humana Press.
5. Weaver EA, Barry MA. 2013. Low Seroprevalent Species D Adenovirus Vectors as Influenza Vaccines. *PLOS ONE* 8:e73313.
6. Atasheva S, Yao J, Shayakhmetov DM. 2019. Innate immunity to adenovirus: lessons from mice. *FEBS Lett* 593:3461–3483.
7. Ahi YS, Bangari DS, Mittal SK. 2011. Adenoviral Vector Immunity: Its Implications and circumvention strategies. *Curr Gene Ther* 11:307–320.
8. Dakin RS, Parker AL, Delles C, Nicklin SA, Baker AH. 2015. Efficient transduction of primary vascular cells by the rare adenovirus serotype 49 vector. *Hum Gene Ther* 26:312–319.
9. Abbink P, Lemckert AAC, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, O'Brien KL, Carville A, Mansfield KG, Goudsmit J, Havenga MJE, Barouch DH. 2007.

- 459 Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus
460 Vaccine Vectors from Subgroups B and D. *J Virol* 81:4654–4663.
- 461 10. Zhao H, Xu C, Luo X, Wei F, Wang N, Shi H, Ren X. 2018. Seroprevalence of Neutralizing Antibodies
462 against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients. *Front*
463 *Immunol* 9.
- 464 11. Teigler JE, Iampietro MJ, Barouch DH. 2012. Vaccination with Adenovirus Serotypes 35, 26, and 48
465 Elicits Higher Levels of Innate Cytokine Responses than Adenovirus Serotype 5 in Rhesus Monkeys.
466 *J Virol* 86:9590–9598.
- 467 12. Dyer A, Di Y, Calderon H, Illingworth S, Kueberuwa G, Tedcastle A, Jakeman P, Chia SL, Brown A,
468 Silva MA, Barlow D, Beadle J, Hermiston T, Ferguson DJ, Champion B, Fisher KD, Seymour LW.
469 2017. Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with
470 Membrane Disruption and Release of Inflammatory Mediators. *Mol Ther Oncolytics* 4:18–30.
- 471 13. Di Y, Seymour L, Fisher K. 2014. Activity of a group B oncolytic adenovirus (ColoAd1) in whole
472 human blood. *Gene Ther* 21:440–443.
- 473 14. 2009. Human adenovirus B strain ColoAd1, complete genome.
- 474 15. Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV
475 and/or MVA-BN-Filo - Full Text View - ClinicalTrials.gov.
- 476 16. A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV - Full Text View -
477 ClinicalTrials.gov.
- 478 17. Vogels R, Zuijdgheest D, Rijnsoever R van, Hartkoorn E, Damen I, Béthune M-P de, Kostense S,
479 Penders G, Helmus N, Koudstaal W, Cecchini M, Wetterwald A, Sprangers M, Lemckert A, Ophorst

- 480 O, Koel B, Meerendonk M van, Quax P, Panitti L, Grimbergen J, Bout A, Goudsmit J, Havenga M.
481 2003. Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination:
482 Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity. *J Virol* 77:8263–
483 8271.
- 484 18. Schnurr D, Dondero ME. 1993. Two New Candidate Adenovirus Serotypes. *Intervirology* 36:79–83.
- 485 19. De Jong JC, Wermenbol AG, Verweij-Uijterwaal MW, Slaterus KW, Wertheim-Van Dillen P, Van
486 Doornum GJJ, Khoo SH, Hierholzer JC. 1999. Adenoviruses from Human Immunodeficiency Virus-
487 Infected Individuals, Including Two Strains That Represent New Candidate Serotypes Ad50 and
488 Ad51 of Species B1 and D, Respectively. *J Clin Microbiol* 37:3940–3945.
- 489 20. Ishiko H, Shimada Y, Konno T, Hayashi A, Ohguchi T, Tagawa Y, Aoki K, Ohno S, Yamazaki S. 2008.
490 Novel Human Adenovirus Causing Nosocomial Epidemic Keratoconjunctivitis. *J Clin Microbiol*
491 46:2002–2008.
- 492 21. 2016. Human adenovirus 49 gene for fiber protein, partial cds, strain: T87-677.
- 493 22. Al Qurashi YMA, Alkhalaf MA, Lim L, Guiver M, Cooper RJ. 2012. Sequencing and phylogenetic
494 analysis of the hexon, fiber, and penton regions of adenoviruses isolated from AIDS patients. *J Med*
495 *Virol* 84:1157–1165.
- 496 23. Lemckert AAC, Grimbergen J, Smits S, Hartkoorn E, Holterman L, Berkhout B, Barouch DH, Vogels
497 R, Quax P, Goudsmit J, Havenga MJE. 2006. Generation of a novel replication-incompetent
498 adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism
499 and immunogenicity. *J Gen Virol* 87:2891–2899.

- 500 24. Baker AT, Mundy RM, Davies JA, Rizkallah PJ, Parker AL. 2019. Human adenovirus type 26 uses
501 sialic acid-bearing glycans as a primary cell entry receptor. *Sci Adv* 5:eaax3567.
- 502 25. Gaggar A, Shayakhmetov DM, Lieber A. 2003. CD46 is a cellular receptor for group B adenoviruses.
503 *Nat Med* 9:1408–1412.
- 504 26. Roelvink PW, Lizonova A, Lee JGM, Li Y, Bergelson JM, Finberg RW, Brough DE, Kovesdi I, Wickham
505 TJ. 1998. The Coxsackievirus-Adenovirus Receptor Protein Can Function as a Cellular Attachment
506 Protein for Adenovirus Serotypes from Subgroups A, C, D, E, and F. *J Virol* 72:7909–7915.
- 507 27. Shayakhmetov DM, Lieber A. 2000. Dependence of Adenovirus Infectivity on Length of the Fiber
508 Shaft Domain. *J Virol* 74:10274–10286.
- 509 28. Nicklin SA, Wu E, Nemerow GR, Baker AH. 2005. The influence of adenovirus fiber structure and
510 function on vector development for gene therapy. *Mol Ther* 12:384–393.
- 511 29. Alba R, Bradshaw AC, Mestre-Francés N, Verdier J-M, Henaff D, Baker AH. 2012. Coagulation factor
512 X mediates adenovirus type 5 liver gene transfer in non-human primates (*Microcebus murinus*).
513 *Gene Ther* 19:109–113.
- 514 30. Alba R, Bradshaw AC, Parker AL, Bhella D, Waddington SN, Nicklin SA, van Rooijen N, Custers J,
515 Goudsmit J, Barouch DH, McVey JH, Baker AH. 2009. Identification of coagulation factor (F)X
516 binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and
517 gene transfer. *Blood* 114:965–971.
- 518 31. Parker AL, Waddington SN, Nicol CG, Shayakhmetov DM, Buckley SM, Denby L, Kembell-Cook G, Ni
519 S, Lieber A, McVey JH, Nicklin SA, Baker AH. 2006. Multiple vitamin K-dependent coagulation
520 zymogens promote adenovirus-mediated gene delivery to hepatocytes. *Blood* 108:2554–2561.

- 521 32. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H, Pink R, Buckley SMK, Greig JA,
522 Denby L, Custers J, Morita T, Francischetti IMB, Monteiro RQ, Barouch DH, Rooijen N van, Napoli C,
523 Havenga MJE, Nicklin SA, Baker AH. 2008. Adenovirus Serotype 5 Hexon Mediates Liver Gene
524 Transfer. *Cell* 132:397–409.
- 525 33. Burmeister WP, Guilligay D, Cusack S, Wadell G, Arnberg N. 2004. Crystal Structure of Species D
526 Adenovirus Fiber Knobs and Their Sialic Acid Binding Sites. *J Virol* 78:7727–7736.
- 527 34. Arnberg N, Edlund K, Kidd AH, Wadell G. 2000. Adenovirus Type 37 Uses Sialic Acid as a Cellular
528 Receptor. *J Virol* 74:42–48.
- 529 35. Vassal-Stermann E, Effantin G, Zubieta C, Burmeister W, Iseni F, Wang H, Lieber A, Schoehn G,
530 Fender P. 2019. CryoEM structure of adenovirus type 3 fibre with desmoglein 2 shows an unusual
531 mode of receptor engagement. *Nat Commun* 10:1181.
- 532 36. Baker AT, Greenshields-Watson A, Coughlan L, Davies JA, Uusi-Kerttula H, Cole DK, Rizkallah PJ,
533 Parker AL. 2019. Diversity within the adenovirus fiber knob hypervariable loops influences primary
534 receptor interactions. *Nat Commun* 10:741.
- 535 37. Smith T, Idamakanti N, Kylefjord H, Rollence M, King L, Kaloss M, Kaleko M, Stevenson SC. 2002. In
536 Vivo Hepatic Adenoviral Gene Delivery Occurs Independently of the Coxsackievirus–Adenovirus
537 Receptor. *Mol Ther* 5:770–779.
- 538 38. Jakubczak JL, Rollence ML, Stewart DA, Jafari JD, Seggern DJV, Nemerow GR, Stevenson SC,
539 Hallenbeck PL. 2001. Adenovirus Type 5 Viral Particles Pseudotyped with Mutagenized Fiber
540 Proteins Show Diminished Infectivity of Coxsackie B-Adenovirus Receptor-Bearing Cells. *J Virol*
541 75:2972–2981.

- 542 39. Vassal-Stermann E, Mottet M, Ducournau C, Iseni F, Vragliau C, Wang H, Zubieta C, Lieber A,
543 Fender P. 2018. Mapping of Adenovirus of serotype 3 fibre interaction to desmoglein 2 revealed a
544 novel 'non-classical' mechanism of viral receptor engagement. *Sci Rep* 8.
- 545 40. Trinh HV, Lesage G, Chennampampil V, Vollenweider B, Burckhardt CJ, Schauer S, Havenga M,
546 Greber UF, Hemmi S. 2012. Avidity Binding of Human Adenovirus Serotypes 3 and 7 to the
547 Membrane Cofactor CD46 Triggers Infection. *J Virol* 86:1623–1637.
- 548 41. Uusi-Kerttula H, Davies JA, Thompson J, Wongthida P, Evgin L, Shim KG, Bradshaw A, Baker AT,
549 Rizkallah PJ, Jones R, Hanna L, Hudson E, Vile R, Chester JD, Parker AL. 2018. Ad5NULL-A20 - a
550 tropism-modified, $\alpha\beta 6$ integrin-selective oncolytic adenovirus for epithelial ovarian cancer
551 therapies. *Clin Cancer Res clincanres*.1089.2018.
- 552 42. Loskog A, Maleka A, Mangsbo S, Svensson E, Lundberg C, Nilsson A, Krause J, Agnarsdottir M,
553 Sundin A, Ahlstrom H, Totterman TH, Ullenhag G. 2016. Immunostimulatory AdCD40L gene
554 therapy combined with low-dose cyclophosphamide in metastatic melanoma patients. *Br J Cancer*
555 114:872–80.
- 556 43. Man YKS, Davies JA, Coughlan L, Pantelidou C, Blázquez-Moreno A, Marshall JF, Parker AL, Halldén
557 G. 2018. The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to $\alpha\beta 6$ Integrins
558 Efficiently Eliminates Pancreatic Cancer Cells. *Mol Cancer Ther* 17:575–587.
- 559 44. Onimaru M, Ohuchida K, Nagai E, Mizumoto K, Egami T, Cui L, Sato N, Uchino J, Takayama K,
560 Hashizume M, Tanaka M. 2010. Combination with low-dose gemcitabine and hTERT-promoter-
561 dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk
562 mechanisms in pancreatic cancer. *Cancer Lett* 294:178–86.

- 563 45. Wang W, Ji W, Hu H, Ma J, Li X, Mei W, Xu Y, Hu H, Yan Y, Song Q, Li Z, Su C. 2013. Survivin
564 promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in
565 gastric cancer immunotherapy. *Oncotarget* 5:150–160.
- 566 46. Jurrus E, Engel D, Star K, Monson K, Brandi J, Felberg LE, Brookes DH, Wilson L, Chen J, Liles K, Chun
567 M, Li P, Gohara DW, Dolinsky T, Konecny R, Koes DR, Nielsen JE, Head-Gordon T, Geng W, Krasny R,
568 Wei G-W, Holst MJ, McCammon JA, Baker NA. 2018. Improvements to the APBS biomolecular
569 solvation software suite. *Protein Sci Publ Protein Soc* 27:112–128.
- 570 47. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Söding
571 J, Thompson JD, Higgins DG. 2011. Fast, scalable generation of high-quality protein multiple
572 sequence alignments using Clustal Omega. *Mol Syst Biol* 7:539–539.
- 573 48. Li W, Cowley A, Uludag M, Gur T, McWilliam H, Squizzato S, Park YM, Buso N, Lopez R. 2015. The
574 EMBL-EBI bioinformatics web and programmatic tools framework. *Nucleic Acids Res* 43:W580-4.
- 575 49. Schrödinger, LLC. The PyMOL Molecular Graphics System, Version 2.0.
- 576

577 **Figure Legends:**

578 **Figure 1: HAdV-C5/D49K infection is not dependent upon CAR or CD46.** Transduction assays were
579 performed in Chinese Hamster Ovary (CHO) cells stably expressing CAR (A), CHO-BC1 cells, stably
580 expressing human CD46 isoform BC1 (B), or CHO-K1 cells, which do not express any known adenovirus
581 fiber-knob receptors (C, D). Cells were infected with 5,000 viral particles per cell of replication deficient
582 HAdV-C5, HAdV-C5/B35K, or HAdV-C5/49K expressing a GFP transgene (A-C), or HAdV-C5, HAdV-C5/49K
583 or HAdV-C5/49F expressing luciferase (D). n=3 error is \pm SD

584 **Figure 2: HAdV-C5/49K transduction is not dependent upon HSPGs, sialic acid bearing glycans or**
585 **Desmoglein 2 (DSG2).** Transduction assays were performed in CHO-K1 (A) or SKOV-3 (B) cells with and
586 without heparinase pre-treatment. As a positive control, HAdV-C5 assays also were performed also in
587 the presence of 10 μ g/ml of FX. Transduction assays were performed with the indicated viral vectors in
588 CHO-K1 (C) or SKOV-3 (D) cells which had been pre-treated with neuraminidase to cleave cell surface
589 sialic acid. Cells were infected with 5,000 viral particles per cell of replication deficient HAdV-C5, HAdV-
590 C5/B35K, or HAdV-C5/49K expressing a GFP transgene, n=3 error is \pm SD. *= P<0.05, **= P<0.01, ***=
591 P<0.005, ****= P<0.001 based on non-parametric Mann-Whitney test.

592 **Figure 3: HAdV-D49K interacts with CAR but is not dependent upon it as an entry receptor.** Surface
593 plasmon resonance to detect potential interactions between HAdV-D49K or HAdV-D49.KO1.K and CAR,
594 CD46 and DSG2 (A). Antibody binding inhibition assays to assess the ability of recombinant HAdV-D49K
595 to inhibit antibody binding to CHO-CAR or CHO-BC1 cells (B). Blocking of HAdV-C5 mediated
596 transduction was studied by preincubation of CHO-CAR cells with HAdV-C5K (C) or HAdV-D49K (D).
597 Blocking of HAdV-C5/D49K mediated transduction was studied by preincubation of CHO-CAR cells with
598 HAdV-C5K (E) or HAdV-D49K (F). Blocking of HAdV-C5/D49K mediated transduction was studied by
599 preincubation of CHO-K1 cells with HAdV-C5K (G) or HAdV-D49K (H). Cells were infected with 5,000 viral

600 particles per cell of replication deficient HAdV-C5 or HAdV-C5/D49K expressing a luciferase transgene,
601 with and without blockade by 20 μ g of recombinant HAdV-C5 or HAdV-D49 fiber knob protein. n=3 error
602 is \pm SD. *= P<0.05, **= P<0.01 based on non-parametric Mann-Whitney test.

603 **Figure 4: HAdV-D49K differs from HAdV-D30K in only three surface exposed amino acids but**
604 **demonstrates radically altered cellular tropism.** Clustal Ω sequence alignment (numbering based on
605 whole fiber sequence) of HAdV-D30K and HAdV-D49K (A). Viewed from the apex down the three fold
606 axis, as if towards the viral capsid, the crystal structures of HAdV-D30K (B) and HAdV-D49K (C) reveal
607 that three of these residues are surface exposed. These residues can be seen projecting into the solvent
608 from loops on the apex of HAdV-D30K (D) and HAdV-D49K (E), residue numbers and names correspond
609 to the fiber-knob protein depicted in that frame. Sticks representing residues belonging to HAdV-D30K
610 and HAdV-D49K are seen in pink and green, respectively. Transduction assays were performed to assess
611 tropism of HAdV-C5/D30K, HAdV-C5/D49K and HAdV-C5/D49.KO1.K in CHO-CAR cells (F) and CHO-K1
612 cells (G). Cells were infected with 5,000 viral particles per cell of replication deficient HAdV-C5 or HAdV-
613 C5/D49K expressing a luciferase transgene, with and without blockade by 20 μ g of recombinant HAdV-C5
614 or HAdV-D49 fiber knob protein.

615 **Figure 5: The residue differences between HAdV-D30K and HAdV-D49K effect the surface electrostatic**
616 **potential of the fiber knob.** The calculated pI of HAdV-D30K and HAdV-D49K is differ as a result of the
617 residue changes, which are shown as green sticks as they occur in that fiber knob protein. The calculated
618 electrostatic surface potential at pH7.35 is projected on a -10mV to +10mV ramp (Red to Blue). HAdV-
619 D49K is seen to have much more basic potential around the apex where the residue substitutions are.

620 **Table 1:** Single crystal diffraction data collection statistics for fiber knob crystal structures determined in
621 this study.

622 **Table 2:** Comparison of transduction of various cancer cell lines by HAdV-C5 and HAdV-C5/D49K. *=

623 $P < 0.05$, **= $P < 0.01$, ***= $P < 0.001$, ****= $P < 0.0001$, ns=not significant based on Student t-test.

624




Figure 1




Figure 2

A	HAdV-D49K			HAdV-D49.K01.K		
	K_{on} ($M^{-1} s^{-1}$)	K_{off} (s^{-1})	K_D (μM)	K_{on} ($M^{-1} s^{-1}$)	K_{off} (s^{-1})	K_D (μM)
CAR	6.1×10^3	0.0012	0.19	nb	nb	No binding
CD46	nb	nb	No binding	nb	nb	No binding
DSG2	nb	nb	No binding	nb	nb	No binding

nm = kinetics too fast to measure
nb = no binding





Figure 3






Figure 4




Figure 5

Table 1: Single crystal diffraction data collection and refinement statistics for fiber knob crystal structures determined in this study.

PDB Entry	6STU – HAdV-D30K	6QPN – HAdV-D49K	6QPO – HAdV-D49K.KO1
Data Collection			
Diamond Beamline	I03	I03	I03
Date	18/04/2019	2017-02-27	2017-02-27
Wavelength	0.95372	0.97628	0.97628
Crystal Data			
Crystallisation Conditions	0.1M SPG, 25% w/v PEG 1500	0.1M MMT [Malic acid, MES, Tris], pH8.0, 25% w/v PEG 1500	0.1 M MMT [Malic acid, MES, Tris], pH 8.0, 25 % w/v PEG 1500
pH	6.0	8.0	8.0
<i>a,b,c</i> (Å)	63.35, 87.36, 217.86	106.83, 56.28, 115.70	105.17, 55.99, 116.03
$\alpha=\beta=\gamma$ (°)	90, 90, 90	90.00, 112.95, 90.00	90.0, 112.47, 90.0
Space group	P 2 ₁ 2 ₁ 2 ₁	P 1 2 1	P 1 2 1
Resolution (Å)	2.39 – 54.76	2.74 – 106.54	2.45 – 57.07
Outer shell	2.39 – 2.45	2.74 – 2.81	2.45 - 2.51
<i>R</i> -merge (%)	0.116 (1.376)	8.2 (163.3)	9.7 (127.4)
<i>R</i> -meas (%)	0.134 (1.583)	9.7 (191.0)	11.4 (149.9)
CC1/2	0.998 (0.623)	0.981 (0.400)	0.994 (0.491)
<i>I</i> / σ (<i>I</i>)	11.2 (1.4)	6.8 (1.0)	9.2 (1.2)
Completeness (%)	100.0 (100.0)	99.1 (98.9)	99.3 (99.3)
Multiplicity	7.5 (7.8)	3.7 (3.7)	3.7 (3.7)
Total Measurements	365,880 (28,110)	122,219 (9,179)	168,773 (12,231)
Unique Reflections	48,897 (3,589)	33,350 (2,461)	45,958 (3,349)
Wilson B-factor(Å ²)	48.7	68.9	59.9
Refinement Statistics			
Total number of refined	9,623	9,083	9,356
<i>R</i> -work reflections	46,478	31,740	43,733
<i>R</i> -free reflections	2,348	1,609	2,225
<i>R</i> -work/ <i>R</i> -free (%)	21.4 / 26.3	21.1 / 25.9	19.4 / 23.5
rms deviations			
Bond lengths (Å)	0.009	0.009	0.012
Bond Angles (°)	1.767	1.688	1.928
¹ Coordinate error	0.288	0.369	0.264
Mean B value (Å ²)	60.2	94.3	80.5
Ramachandran Statistics			
Favoured/allowed/Outliers	1090 / 107 / 10	1004 / 104 / 35	1065 / 87 / 36
%	90.3 / 8.9 / 0.8	87.8 / 9.1 / 3.1	89.7 / 7.3 / 3.0

Table 2: Comparison of transduction of various cancer cell lines by HAdV-C5 and HAdV-C5/D49K. *= P<0.05, **=P<0.01, ***=P<0.001, ****=P<0.0001, ns=not significant

Cancer Type	Cell Line Name	Level of HAdV-C5 Infection (RLU/mg total protein)	Level of HAdV-C5/D49K Infection (RLU/mg total protein)	Change in infectivity (Fold change HAdV-C5/D49K divided by HAdV-C5 RLU/mg)	Statistical Significance (p value)
Pancreatic Adenocarcinoma, derived from acitic metastasis	ASPC1	3.9E+04	1.2E+06	30.7	**
Pancreatic Adenocarcinoma	BXPC3	1.2E+04	2.5E+06	210.9	**
Pancreatic Adenocarcinoma	Panc10	1.0E+05	7.2E+06	69.2	****
Pancreatic Adenocarcinoma, derived from splenic metastasis	SW1990	9.6E+04	1.1E+06	11.3	****
Pancreatic Adenocarcinoma	MIA PaCa2	3.4E+05	1.4E+06	4.2	**
Pancreatic Adenocarcinoma, derived from liver metastasis	Suit2	6.0E+04	1.3E+06	22.2	*
Pancreatic Ductal Adenocarcinoma	PANC 0403	1.2E+04	4.0E+05	33.0	*
Pancreatic Ductal Adenocarcinoma, Derived from liver metastasis	CFPAC-1	1.8E+04	1.1E+06	62.0	***
Pancreatic Ductal Adenocarcinoma	PT45	3.9E+05	2.0E+06	5.1	**
Breast Carcinoma	BT-20	1.8E+03	8.6E+05	481.2	*

Breast Ductal Carcinoma	BT-474	6.5E+03	1.4E+05	21.8	*
Breast Adenocarcinoma, derived from brain metastasis	MDA-MB-361	2.2E+05	1.5E+06	6.7	**
Breast Adenocarcinoma, derived from plural effusion metastasis	MDA-MB-231	3.3E+04	1.5E+05	4.6	*
Breast Adenocarcinoma, derived from plural effusion metastasis	MCF7	1.3E+04	6.6E+06	497.3	***
Large Lung Cell Carcinoma	NCI-H460	2.1E+05	3.9E+06	18.8	*
Lung Carcinoma	A427	1.2E+07	7.2E+06	0.6	*
Lung Carcinoma	A549	2.8E+06	6.9E+06	2.5	***
Esophageal Squamous Cell Carcinoma	Kyse-30	6.3E+05	1.4E+07	22.4	***
Colorectal Adenocarcinoma, Duke's Type C	DLD-1	6.0E+06	5.0E+06	0.8	ns
Ovarian Adenocarcinoma	SKOV-3	9.1E+05	7.7E+06	8.5	**
Gastric tubular adenocarcinoma	MKN28	2.6E+05	2.0E+07	76.9	***
Gastric adenocarcinoma	MKN45	3.1E+04	2.2E+06	71.0	***